TY - JOUR
T1 - Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management
T2 - results of a randomised controlled trial
AU - van der Hout, A.
AU - Jansen, F.
AU - van Uden-Kraan, C. F.
AU - Coupé, V. M.
AU - Holtmaat, K.
AU - Nieuwenhuijzen, G. A.
AU - Hardillo, J. A.
AU - de Jong, R. J.Baatenburg
AU - Tiren-Verbeet, N. L.
AU - Sommeijer, D. W.
AU - de Heer, K.
AU - Schaar, C. G.
AU - Sedee, R. J.E.
AU - Bosscha, K.
AU - van den Brekel, M. W.M.
AU - Petersen, J. F.
AU - Westerman, M.
AU - Honings, J.
AU - Takes, R. P.
AU - Houtenbos, I.
AU - van den Broek, W. T.
AU - de Bree, R.
AU - Jansen, P.
AU - Eerenstein, S. E.J.
AU - Leemans, C. R.
AU - Zijlstra, J. M.
AU - Cuijpers, P.
AU - van de Poll-Franse, L. V.
AU - Verdonck-de Leeuw, I. M.
PY - 2020
Y1 - 2020
N2 - Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.
AB - Purpose: The eHealth self-management application ‘Oncokompas’ was developed to support cancer survivors in monitoring health-related quality of life (HRQOL) and symptoms, and obtaining personalized feedback and options for supportive care. The aim of this study was to assess the cost-utility of Oncokompas compared with care as usual (CAU) among cancer survivors. Methods: Survivors were randomly allocated to the intervention or control group. Direct (non-)medical, indirect non-medical costs, and HRQOL were measured at 3- and 6-month follow-up, using iMTA Medical Consumption and Productivity Costs and the EuroQol-5D questionnaires. Mean cumulative costs and quality-adjusted life-years (QALYs) were compared between both groups. Results: In total, 625 survivors were randomized into intervention (n = 320) or control group (n = 305). Base case analysis showed that incremental costs from a societal perspective were − €163 (95% CI, − 665 to 326), and incremental QALYs were 0.0017 (95% CI, − 0.0121 to 0.0155) in the intervention group compared with those in the control group. The probability that, compared with CAU, Oncokompas is more effective was 60%, less costly 73%, and both more effective and less costly 47%. Sensitivity analyses showed that incremental costs vary between − €40 and €69, and incremental QALYs vary between − 0.0023 and − 0.0057. Conclusion: Oncokompas is likely to be equally effective on utilities, and not more expensive than CAU, and will therefore contribute to sustainable cancer survivorship care in a (cost-)effective manner. Implications for Cancer Survivors: Oncokompas seems to improve HRQOL and reduces the burden of several tumour-specific symptoms, while costs from a societal perspective are similar to CAU.
KW - Cancer survivorship
KW - Cost-utility
KW - eHealth
KW - Quality of life
KW - Self-management
KW - Supportive care
UR - http://www.scopus.com/inward/record.url?scp=85087776668&partnerID=8YFLogxK
U2 - 10.1007/s11764-020-00912-9
DO - 10.1007/s11764-020-00912-9
M3 - Article
C2 - 32656739
AN - SCOPUS:85087776668
JO - Journal of Cancer Survivorship
JF - Journal of Cancer Survivorship
SN - 1932-2259
ER -